No Data
Zai Lab Limited (NASDAQ:ZLAB): When Will It Breakeven?
Hong Kong stock movement | ZAI LAB (09688) rises over 8% as "Ripretinib" new indications are proposed for priority review.
ZAI LAB (09688) rose over 8%. As of the time of writing, it increased by 8.29%, reaching 22.85 HKD, with a transaction volume of 54.3165 million HKD.
Goldman Sachs released a deep investment value report on China's Biomedical sector, highlighting a bullish outlook on ZAI LAB (ZLAB.US/9688.HK) and four other companies.
Recently, Goldman Sachs released an in-depth investment value analysis report on China's biotechnology. Goldman Sachs believes that it remains Bullish on the biotechnology sector within China's Medical and Healthcare market, as China's innovation is gaining and will continue to gain Global recognition. A number of leading biotechnology companies are expected to achieve breakeven in 2025/2026. This profitability inflection point is of milestone significance for China's biotechnology industry. Goldman Sachs also stated that ZAI LAB (ZLAB.US/9688.HK), Legend Biotech, INNOCARE, BEIGENE, and INNOVENT BIO are preferred symbols, as these companies have all experienced core catalytic events this year.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
SA Asks: Which Big Pharmas Would Be Most Impacted by Higher Tariffs?
Press Release: Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
